THDOC

The adrenal, stress-driven counterpart to allopregnanolone; a potent GABA-A positive modulator that couples the corticosteroid axis to inhibitory tone.

THDOC is a normal constituent of human plasma and brain rather than a marketed medicine, so it has no established clinical safety profile or approved formulation. Its actions are those of the GABAergic neurosteroid class; supraphysiological exposure in animals produces dose-dependent sedation, motor incoordination, and ultimately anesthesia, consistent with strong GABA-A potentiation.

Class-level considerations also include tolerance and withdrawal-like states, in which a rapid fall in inhibitory neurosteroid tone is associated with heightened neuronal excitability, anxiety, and increased seizure susceptibility; the perimenstrual worsening of catamenial epilepsy is the clinical correlate of such neurosteroid withdrawal. Because THDOC arises from the corticosteroid pathway, its levels are entangled with adrenal function and can be shifted by stress, disease, and drugs that alter steroidogenesis. Human exposure data for administered THDOC are lacking, and its poor oral bioavailability and rapid metabolism make it impractical as an oral agent.

The metabolic fate of deoxycorticosterone was studied as early as 1961, when Pasqualini and Jayle identified a tetrahydro-DOC glucuronide in urine after administration of the parent steroid, establishing that DOC is reduced to tetrahydrogenated derivatives in vivo. The neuroactive significance of these metabolites emerged in 1986, when Majewska and colleagues reported in Science that reduced steroid metabolites, including THDOC, act as barbiturate-like modulators of the GABA-A receptor, and when Crawley and colleagues described the anxiolytic activity of what they termed an endogenous adrenal steroid, later identified as THDOC.

Structure-activity work by Harrison and colleagues in 1987 defined the 3-alpha-hydroxy, 5-alpha-reduced configuration as essential for GABAergic potency. The stress connection was cemented in 1991 by Purdy and colleagues, who showed that acute stress rapidly elevates brain THDOC and allopregnanolone, and it was extended by Reddy and Rogawski in 2002, who demonstrated that stress- and DOC-derived THDOC modulates GABA-A function and seizure susceptibility in a 5-alpha-reductase-dependent manner. The 2003 demonstration by Stell and colleagues that such neurosteroids selectively enhance delta-subunit tonic inhibition anchored THDOC within the modern extrasynaptic-receptor framework.

Within neuropharmacology, THDOC occupies a respected but understudied niche as the adrenal, deoxycorticosterone-derived counterpart to allopregnanolone. It is frequently invoked as a proof-of-concept molecule for the idea that the brain converts stress steroids into rapidly acting inhibitory neuromodulators, yet, unlike allopregnanolone (whose synthetic equivalents brexanolone and zuranolone reached the clinic), THDOC has not itself been developed into an approved medicine.

Instead it is valued as an endogenous mediator and candidate biomarker: its levels rise during experimentally induced panic, fall during perimenstrual catamenial epilepsy, and shift with antidepressant treatment, and it serves as a standard pharmacological tool for probing delta-subunit extrasynaptic GABA-A receptors. It has essentially no presence as a nutritional supplement or recreational substance, and its reputation is confined largely to the basic and translational literature on stress, epilepsy, and neurosteroid signaling.